Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference Chemomab presents new data supporting clinical potential of CM-101 as novel treatment for PSC at EASL 2024 and Gordon Research Conference

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for...